Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03232073 · ClinicalTrials.gov registry record · Phase 3
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
A Phase 3 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 877
- Enrollment target
NCT03232073 is a Phase 3 study that has completed, run by Actelion. The registered enrollment target is 877 participants.
The verdict
NCT03232073, a Phase 3 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 877 participants
- Enrollment target
Study Summary
The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS). The AC-058B303 study is the long-term extension for the core study AC-058B301. The purpose of this long term extension of the core study AC-058B301 is to characterize the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with RMS.
Interventions
- DRUG Ponesimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 877 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2024-01-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03232073
The ClinicalTrials.gov registry entry for NCT03232073 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 877 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ponesimod is the first listed.
NCT03232073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03232073 about?
NCT03232073 is a clinical study titled "Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis". The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS). The AC-058B303 study is the long-term extension for the core study AC-058B301. The purpose of this long term extension ...
What is the current status of trial NCT03232073?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 877 participants. The study started on 2017-07-05. Estimated completion is 2024-01-16.
What interventions are being tested in trial NCT03232073?
The interventions under investigation include: Ponesimod (DRUG).
Who is sponsoring clinical trial NCT03232073?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.